Mark J Taylor Selected Research

Doxycycline (Periostat)

1/2021	Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis.
3/2020	Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis?
12/2019	Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol.
1/2019	Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis.
1/2018	Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis.
1/2018	Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model.
1/2017	Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis.
10/2016	Wolbachia endosymbionts induce neutrophil extracellular trap formation in human onchocerciasis.
3/2016	Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis.
4/2015	Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark J Taylor Research Topics

Disease

29	Onchocerciasis 06/2022 - 03/2002
24	Infections 12/2022 - 11/2003
20	Filarial Elephantiasis (Lymphatic Filariasis) 12/2022 - 11/2003
12	Filariasis 01/2021 - 06/2005
10	Loiasis 01/2021 - 04/2005
6	Neglected Diseases 01/2019 - 03/2014
6	Ocular Onchocerciasis (River Blindness) 01/2019 - 06/2003
5	Intestinal Volvulus (Volvulus) 10/2016 - 04/2005
4	Eosinophilia 01/2020 - 11/2003
4	Coinfection 01/2019 - 11/2003
4	Inflammation (Inflammations) 07/2011 - 06/2003
3	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 12/2021 - 01/2019
3	Infertility (Sterility) 03/2020 - 01/2017
3	Keratitis 08/2009 - 04/2006
2	Autism Spectrum Disorder 12/2020 - 01/2019
2	Reinfection 02/2020 - 04/2015
2	Cutaneous Leishmaniasis 10/2016 - 02/2016
2	Fever (Fevers) 05/2008 - 03/2002
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2022
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022
1	Lymphedema (Milroy Disease) 01/2021
1	Trichuriasis 01/2021
1	Nematode Infections 01/2020
1	Mania (Manias) 01/2019
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2019
1	Schizophrenia (Dementia Praecox) 01/2019
1	Tic Disorders (Tic Disorder) 01/2019
1	Major Depressive Disorder (Major Depressive Disorders) 01/2019
1	Malaria 06/2018
1	Parasitic Diseases (Parasitic Disease) 02/2016
1	HIV Infections (HIV Infection) 06/2005
1	Brain Diseases (Brain Disorder) 04/2005
1	Tachycardia (Tachyarrhythmias) 03/2002

Drug/Important Bio-Agent (IBA)

20	Doxycycline (Periostat)FDA LinkGeneric 01/2021 - 06/2005
18	Ivermectin (Mectizan)FDA Link 06/2022 - 03/2002
18	Pharmaceutical PreparationsIBA 12/2020 - 11/2003
10	Anti-Bacterial Agents (Antibiotics)IBA 12/2022 - 06/2003
5	Albendazole (Albenza)FDA Link 11/2017 - 11/2003
5	Diethylcarbamazine (Hetrazan)FDA Link 07/2011 - 03/2002
4	Lipoproteins (Lipoprotein)IBA 10/2016 - 08/2009
3	AnthelminticsIBA 03/2020 - 01/2019
3	Minocycline (Cyclops)FDA LinkGeneric 01/2019 - 03/2016
3	Rifampin (Rifampicin)FDA LinkGeneric 01/2018 - 07/2010
3	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2016 - 08/2009
2	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2021 - 01/2020
2	AntigensIBA 02/2020 - 04/2006
2	CytokinesIBA 02/2020 - 01/2020
2	QuinazolinesIBA 01/2020 - 01/2019
2	Tetracycline (Achromycin)FDA LinkGeneric 01/2019 - 03/2006
2	Interleukin-4 (Interleukin 4)IBA 01/2018 - 11/2003
2	Toll-Like Receptor 2IBA 10/2016 - 12/2007
1	ChitinasesIBA 12/2022
1	LithiumIBA 01/2022
1	MelatoninIBA 01/2022
1	SugarsIBA 12/2021
1	TetracyclinesIBA 01/2021
1	benzimidazoleIBA 01/2021
1	Modafinil (Provigil)FDA Link 12/2020
1	ORALIT (ORS)IBA 12/2020
1	Amphetamine (Amfetamine)FDA LinkGeneric 12/2020
1	Methylphenidate (Ritalin)FDA LinkGeneric 12/2020
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 12/2020
1	Small Molecule LibrariesIBA 03/2020
1	ChemokinesIBA 02/2020
1	Immunoglobulins (Immunoglobulin)IBA 02/2020
1	Interleukin-13IBA 01/2020
1	OrganophosphatesIBA 12/2019
1	TemefosIBA 12/2019
1	InterleukinsIBA 01/2019
1	PleuromutilinsIBA 01/2019
1	SolutionsIBA 01/2019
1	flubendazoleIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	tyramine-deoxysorbitolIBA 01/2019
1	BoronIBA 01/2019
1	MacrolidesIBA 01/2019
1	InsecticidesIBA 06/2018
1	Chemokine ReceptorsIBA 01/2018
1	lipophosphonoglycanIBA 10/2016
1	GlycolipidsIBA 10/2016
1	autoclaved Leishmania major vaccineIBA 02/2016
1	PAM2-CSK4IBA 02/2016
1	VaccinesIBA 02/2016
1	Leishmaniasis VaccinesIBA 02/2016
1	DNA (Deoxyribonucleic Acid)IBA 02/2016
1	LipopeptidesIBA 02/2016
1	LigandsIBA 10/2010
1	Apolipoproteins C (ApoC)IBA 08/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2009
1	CXC ChemokinesIBA 12/2007
1	Myeloid Differentiation Factor 88IBA 04/2006
1	MTT formazanIBA 03/2006
1	Interleukin-5 (Interleukin 5)IBA 11/2003

Therapy/Procedure

9	Therapeutics 01/2021 - 09/2008
5	Mass Drug Administration 01/2021 - 08/2009
3	Drug Therapy (Chemotherapy) 01/2021 - 06/2003
2	Aftercare (After-Treatment) 01/2020 - 04/2015
1	Injections 01/2019
1	Ligation 10/2016
1	Contraindications 07/2010